NCT06772220NARecruiting

Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease

Oregon Health and Science University

Start Date

3/5/2024

Completion Date

12/31/2025

Summary

This is a research study investigating elevated homocysteine in the blood of patients with Parkinson's disease who are currently receiving treatment with levodopa. We are evaluating if elevated homocysteine can be corrected using open label B vitamin therapy, as well as the impact of homocysteine levels on cognitive function.

Eligibility Criteria

Age Range: 40 years to 90 years

Inclusion Criteria: 1. Diagnosis of probable Parkinson's Disease according to Movement Disorders Society criteria. 2. Currently treated with levodopa at a minimum dose of 300 mg/day 3. Montreal Cognitive Assessment (MOCA) ≥15 4. Demonstrated capacity to provide informed consent. 5. 40-90 years of age 6. Estimated glomerular filtration rate ≥60 7. Absence of uncontrolled hypertension in medical history 8. Absence of insulin use Exclusion Criteria: \-

Interventions

DIETARY_SUPPLEMENT

Folic Acid 1 MG

DIETARY_SUPPLEMENT

Vitamin B6 25 MG

DIETARY_SUPPLEMENT

Vitamin B12

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Parkinson&Amp;#39;s Disease

Locations

Oregon Health & Science University (OHSU)

Portland, Oregon 97239

United States